Background Only small randomized trials have investigated the efficacy and safety of direct
oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in patients with …

Trombose venosa profunda é uma das principais causas de morbidade hospitalar e
ambulatorial, seja em pacientes clínicos, seja em pacientes cirúrgicos, impactando …

Background There are no clear dosing recommendations when using apixaban for venous
thromboembolism (VTE) treatment in patients with severe or end-stage renal disease; …

Deep vein thrombosis is one of the main causes of inpatient and outpatient morbidity, both in
medical and surgical patients, significantly impacting mortality statistics and requiring prompt …

Telemedicine and digitalised healthcare have recently seen exponential growth, led, in part,
by increasing efforts to improve patient flexibility and autonomy, as well as drivers from …

Background: Direct oral anticoagulants (DOACs) are preferred over warfarin for many
indications, though their safety has not been well established in patients with acute renal …

Clinically-driven dose reduction of direct oral anticoagulants in individuals with atrial
fibrillation is prevalent worldwide. However, a paucity of evidence to tailor dose selection …

Abstract The popularity of Direct Oral AntiCoagulants (DOACs) for approved indications has
risen dramatically following their introduction to the UK's National Health Service (NHS) due …

Background: Direct oral anticoagulants (DOACs) are increasingly prescribed for the
treatment of venous thromboembolism (VTE). However, little is known regarding …

Dear Editor, Shehi et al.[1] report on a 69-year-old Hispanic man who presented to the
hospital with complaints of right upper quadrant pain for the past 3 days without any history …